Search Results for “FDA” – Page 169 – media

Mercks to Lead Squamous Lung Cancer Treatment With Keytruda

Pharma giant Merck & Co. revealed Keytruda had perfectly completed its final-stage research on the drug for previously untreated patients with skin cancer, who represent about 25% to 30% of the overall market.
- Source: Ddu
- 640
- May 24, 2018
cancer Company Insight Merck
Health-Check-Up Through Sweat Monitoring Wearable Device

Cincinnati-based startup Eccrine System has developed a health wearable devices called Sweatronics which tracks your health using sweat. Other bodily fluids like urine and blood contain plenty of the body information’s but are not as easy to collect. However, Sweatronics needs only sweat samples that is produces automatically while working or even sleeping.
- Source: Ddu
- 1,663
- May 24, 2018
digital health mHealth New Approvals
Opt for Cancer Drug to forgo Tuberculosis

More than one-quarter of the world’s population were constantly getting affected with the one of the world’s oldest and deadliest disease named Tuberculosis (TB). In spite of 6-9 months antibiotic therapy, it’s very difficult to treat tuberculosis. That’s why researchers throughout the world were trying to find the faster ways of cure.
- Source: Ddu
- 587
- May 18, 2018
cancer Researches tuberculosis
LifePlus announces glucose monitoring wearable

The company announced that the innovative product, whose technological details are not known yet, is undergoing clinical trials in five cities across the world. The patent-pending invention is based on open standards software and cloud-based analytics. The system gives users real-time notifications and cloud-based AI solutions.
- Source: Ddu
- 980
- May 18, 2018
Clinical Trials mHealth wearables
AbbVie pressurized to keep low price for Imbruvica formula

This year AbbVie launched Imbruvica, a single tablet for blood cancer treatment. It has been designed as a convenient therapy measure for patients who used the old tablets as often as four times a day. Adapting the new single tablet in their treatment regimens will prove to be an expensive proposition for some patients as the new tablet comes with a price tag of $400 each, triple the cost of the older tablets.
- Source: Ddu
- 1,109
- May 17, 2018
AbbVie Company Insight pharma pharmaceutical
Feds join lawsuits claiming Insys used strip club visits, super-doses and more to boost Subsys sales

Prosecutors have already charged Insys founder John Kapoor and won guilty pleas from two characters in an ongoing kickbacks probe. Now, the Justice Department has escalated the case by joining in with whistleblowers who've detailed a stunning range of techniques the company allegedly used to push its powerful opioid painkiller.
- Source: FiercePharma
- 650
- May 16, 2018
Company Insight lawsuit pharma
Amsterdam airport to be a new site for EU CAR-T manufacturing facility of Gilead

When it comes to manufacturing CAR T drugs (personalized treatments engineering immune cells to destroy cancer cells of patients) speed is of utmost importance. A new manufacturing site has been decided upon by Gilead for Yescarta, its CAR-T therapy at a Netherlands airport.
- Source: drugdu
- 667
- May 16, 2018
cancer CAR T-cells FDA New Approvals
Security issues with Philips, GE, and Silex medical devices

Serious security flaws were discovered in Philips, GE and Silex medical devices that, if exploited, could allow authorized access and let a hacker obtain elevated privileges, according to two separate U.S. Department of Homeland Security ICS-CERT alerts issued this month.
- Source: HealthIT news
- 631
- May 15, 2018
Company Insights cybersecurity medical device
3 Ways 3D Printing Is Changing the Medical Field

Every year, 3D printing offers more and more promise in the healthcare field. And while the ultimate goal of printing whole complex organs for transplants may still be decades away, 3D printing is helping to save and improve lives in ways - and in places - never imagined just a few years ago.
- Source: ASME
- 689
- May 14, 2018
3D printing New Approvals
Biotechnology Company Abpro postpones $69M IPO

According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
- Source: Ddu
- 606
- May 14, 2018
biotech Company Insights IPO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.